NPM1 and acute myeloid leukemia: Up to now, several studies targeting NPM1-mutated AML are undergoing, including inhibiting NPM1c functions, interfering with abnormal transport of NPM1c protein, promoting NPM1c degradation and immunotherapy such as monoclonal antibodies.